These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
92 related articles for article (PubMed ID: 12648895)
1. The clinical use of milnacipran for depression. Morishita S; Arita S Eur Psychiatry; 2003 Feb; 18(1):34-5. PubMed ID: 12648895 [TBL] [Abstract][Full Text] [Related]
2. Differential period of onset of action of fluvoxamine, paroxetine and milnacipran for depression. Morishita S; Arita S Hum Psychopharmacol; 2003 Aug; 18(6):479-82. PubMed ID: 12923828 [TBL] [Abstract][Full Text] [Related]
3. Response rate obtained using milnacipran depending on the severity of depression in the treatment of major depressive patients. Sugawara Y; Higuchi H; Yoshida K; Takahashi H; Kamata M; Naito S; Sato K; Shimizu T Clin Neuropharmacol; 2006; 29(1):6-9. PubMed ID: 16518126 [TBL] [Abstract][Full Text] [Related]
4. Controlled comparison of two different doses of milnacipran in major depressive outpatients. Kanemoto K; Matsubara M; Yamashita K; Tarao Y; Inada E; Sekine T Int Clin Psychopharmacol; 2004 Nov; 19(6):343-6. PubMed ID: 15486520 [TBL] [Abstract][Full Text] [Related]
5. Long-term efficacy and safety of milnacipran compared to clomipramine in patients with major depression. Leinonen E; Lepola U; Koponen H; Mehtonen OP; Rimon R Acta Psychiatr Scand; 1997 Dec; 96(6):497-504. PubMed ID: 9421348 [TBL] [Abstract][Full Text] [Related]
6. A comparative study of milnacipran and imipramine in the treatment of major depressive disorder. Lopez-Ibor JJ; Conesa A; Curr Med Res Opin; 2004 Jun; 20(6):855-60. PubMed ID: 15200743 [TBL] [Abstract][Full Text] [Related]
7. Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: a comparison with fluvoxamine. Clerc G; Int Clin Psychopharmacol; 2001 May; 16(3):145-51. PubMed ID: 11354236 [TBL] [Abstract][Full Text] [Related]
8. Milnacipran and pindolol: a randomized trial of reduction of antidepressant latency. Isaac MT; Isaac MB; Gallo F; Tournoux A Hum Psychopharmacol; 2003 Dec; 18(8):595-601. PubMed ID: 14696018 [TBL] [Abstract][Full Text] [Related]
9. A randomised, double-blind comparison of milnacipran and imipramine in the treatment of depression. Van Amerongen AP; Ferrey G; Tournoux A J Affect Disord; 2002 Oct; 72(1):21-31. PubMed ID: 12204314 [TBL] [Abstract][Full Text] [Related]
10. Comparison of efficacy and safety of milnacipran and fluoxetine in Korean patients with major depression. Lee MS; Ham BJ; Kee BS; Kim JB; Yeon BK; Oh KS; Oh BH; Lee C; Jung HY; Chee IS; Choe BM; Paik IH Curr Med Res Opin; 2005 Sep; 21(9):1369-75. PubMed ID: 16197655 [TBL] [Abstract][Full Text] [Related]
11. Controlled comparison of two doses of milnacipran (F 2207) and amitriptyline in major depressive inpatients. Ansseau M; von Frenckell R; Mertens C; de Wilde J; Botte L; Devoitille JM; Evrard JL; De Nayer A; Darimont P; Dejaiffe G Psychopharmacology (Berl); 1989; 98(2):163-8. PubMed ID: 2569214 [TBL] [Abstract][Full Text] [Related]
12. No predictors of antidepressant patient response to milnacipran were obtained using the three-factor structures of the Montgomery and Asberg Depression Rating Scale in Japanese patients with major depressive disorders. Higuchi H; Sato K; Yoshida K; Takahashi H; Kamata M; Otani K; Yamaguchi N Psychiatry Clin Neurosci; 2008 Apr; 62(2):197-202. PubMed ID: 18412843 [TBL] [Abstract][Full Text] [Related]
13. Milnacipran plasma levels and antidepressant response in Japanese major depressive patients. Higuchi H; Yoshida K; Takahashi H; Naito S; Kamata M; Ito K; Sato K; Tsukamoto K; Shimizu T; Nakanishi M; Hishikawa Y Hum Psychopharmacol; 2003 Jun; 18(4):255-9. PubMed ID: 12766929 [TBL] [Abstract][Full Text] [Related]
14. The alpha 2A-adrenergic receptor gene polymorphism modifies antidepressant responses to milnacipran. Wakeno M; Kato M; Okugawa G; Fukuda T; Hosoi Y; Takekita Y; Yamashita M; Nonen S; Azuma J; Kinoshita T J Clin Psychopharmacol; 2008 Oct; 28(5):518-24. PubMed ID: 18794646 [TBL] [Abstract][Full Text] [Related]
15. Effects of levomilnacipran ER on fatigue symptoms associated with major depressive disorder. Freeman MP; Fava M; Gommoll C; Chen C; Greenberg WM; Ruth A Int Clin Psychopharmacol; 2016 Mar; 31(2):100-9. PubMed ID: 26584326 [TBL] [Abstract][Full Text] [Related]
16. Augmentation of milnacipran by risperidone in treatment for major depression. Tani K; Takei N; Kawai M; Suzuki K; Sekine Y; Toyoda T; Minabe Y; Mori N Int J Neuropsychopharmacol; 2004 Mar; 7(1):55-8. PubMed ID: 14731310 [TBL] [Abstract][Full Text] [Related]
17. Remission rates with milnacipran 100 mg/day and 150 mg/day in the long-term treatment of major depression. Okumura K; Furukawa TA Clin Drug Investig; 2006; 26(3):135-42. PubMed ID: 17163244 [TBL] [Abstract][Full Text] [Related]